Hengrui Pharma(SH:600276) Xin Lang Cai Jing·2025-12-26 12:21Group 1 - The company Heng Rui Medicine (600276.SH) is scheduled to release its 2025 annual report on March 26, 2026 [1][6] - For Q4 2025, the expected revenue is projected to be between 32.072 billion to 36.062 billion RMB, representing a year-on-year growth of 14.6% to 28.9% [2][6] - The expected net profit for Q4 2025 is forecasted to be between 7.882 billion to 10.096 billion RMB, with a year-on-year increase of 24.4% to 59.3% [2][6] Group 2 - In the first three quarters of 2025, Heng Rui Medicine achieved a revenue growth of 14.85% and a net profit growth of 24.50% [3][8] - The company has successfully controlled its expense ratio while improving both gross and net profit margins [8] - Significant achievements in external authorization collaborations include partnerships with GSK, Glenmark, and Braveheart_Bio, involving upfront payments totaling 583 million USD and potential milestone payments up to 14.116 billion USD [4][9] Group 3 - The company has made breakthroughs in its innovative drug pipeline, with multiple new drugs approved for clinical trials and market launch [4][9] - Notable products include China's first independently developed oral hypoglycemic combination drug [9] - The company’s third-quarter results showed revenue, net profit, and net profit excluding non-recurring items of 23.188 billion, 5.751 billion, and 5.589 billion RMB respectively, with year-on-year growth rates of 14.85%, 24.50%, and 21.08% [8][9]